Cited by 98Vitamin D Research StudiesSteroid Chemistry and BiochemistryPharmacogenetics and Drug Metabolism

An alternative pathway of vitamin D2 metabolism: Cytochrome P450scc (CYP11A1)‐mediated conversion to 20‐hydroxyvitamin D2 and 17,20‐dihydroxyvitamin D2

Open access
Slominski, Andrzej, Semak, Igor, Wortsman, Jacobo, Zjawiony, Jordan, Li, Wei, Zbytek, Blazej, Tuckey, Robert C.·2006·The FEBS Journal

Abstract

We report an alternative, hydroxylating pathway for the metabolism of vitamin D 2 in a cytochrome P450 side chain cleavage (P450scc; CYP11A1) reconstituted system. NMR analyses identified solely 20‐hydroxyvitamin D 2 and 17,20‐dihydroxyvitamin D 2 derivatives. 20‐Hydroxyvitamin D 2 was produced at a rate of 0.34 mol·min−1·mol−1 P450scc, and 17,20‐dihydroxyvitamin D 2 was produced at a rate of 0.13 mol·min−1·mol−1. In adrenal mitochondria, vitamin D 2 was metabolized to six monohydroxy products. Nevertheless, aminoglutethimide (a P450scc inhibitor) inhibited this adrenal metabolite formation. Initial testing of metabolites for biological activity showed that, similar to vitamin D 2, 20‐hydroxyvitamin D 2 and 17,20‐dihydroxyvitamin D 2 inhibited DNA synthesis in human epidermal HaCaT keratinocytes, although to a greater degree. 17,20‐Dihydroxyvitamin D 2 stimulated transcriptional activity of the involucrin promoter, again to a significantly greater extent than vitamin D 2, while the effect of 20‐hydroxyvitamin D 2 was statistically insignificant. Thus, P450scc can metabolize vitamin D 2 to generate novel products, with intrinsic biological activity (at least in keratinocytes).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1742-4658.2006.05302.x

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Purified CYP11A1 hydroxylates the vitamin D2 side chain without cleavage, with the preferred initial site at C20.

    “purified CYP11A1 can also hydroxylate the side chain of vitamin D2 without its cleavage, with the preferred site for the initial hydroxylation being at C20”
  • The major products of vitamin D2 metabolism by CYP11A1 are 20(OH)D2 and 17,20(OH)2D2, with lesser production of 17,20,24(OH)3D2 and an unidentified dihydroxyvitamin D2 metabolite.

    “The major products were identified as 20(OH)D2 and 17,20(OH)2D2, with lesser production of 17,20,24(OH)3D2 and another unidentified dihydroxyvitamin D2 metabolite.”
  • Catalytic activity of CYP11A1 on non-traditional substrates such as vitamin D and ergosterol does not result in side chain cleavage, but involves sequential hydroxylations of the side chain including at C17.

    “Importantly, catalytic activity on non-traditional substrates such as vitamin D and ergosterol does not result in side chain cleavage, but involves sequential hydroxylations of the side chain including at C17 [[10,24–30], and see below].”
  • The activity of CYP11A1 is affected by substrate structure: sterols with steroidal or Δ7-steroidal structures undergo side chain cleavage following hydroxylations at C22 and C20, whereas vitamin D metabolism involves sequential hydroxylations starting at C20 without cleavage.

    “The activity of CYP11A1 is affected by the structure of the substrate with sterols having steroidal or Δ7-steroidal structures undergoing side chain cleavage following hydroxylations at C22 and C20. In contrast, metabolism of vitamin D involves sequential hydroxylations that start at C20 but do not lead to cleavage.”
  • Recombinant human CYP11A1 shows a similar sequence of reactions for vitamin D2, with 20(OH)D2 as the major product and lower production of 17,20(OH)2D2 and 17,20,24(OH)3D2 and another unidentified D2 metabolite.

    “A similar sequence of reactions was seen for recombinant human CYP11A1 [9]. The major product was 20(OH)D2 with lower production of 17,20(OH)2D2 and 17,20,24 (OH)3D2 and another unidentified D2 metabolite [28,29].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Slominski, A., Semak, I., Wortsman, J., Zjawiony, J., Li, W., Zbytek, B., & Tuckey, R. C.
Affiliations
  • University of Tennessee Health Science Center (US)
  • Belarusian State University (BY)
  • SIU Medicine (US)
  • University of Mississippi (US)
  • The University of Western Australia (AU)
Venue
The FEBS Journal
Publisher
Wiley
Published
2006-06-05
Volume
273
Issue
13
Pages
2891-2901
ISSN
  • 1742-464X (ISSN-L)
  • 1742-4658
OpenAlex
W2028177638
Cited by
98
References
41
Citations by year
2026: 2 · 2025: 3 · 2024: 5 · 2023: 4 · 2022: 3 · 2021: 4 · 2020: 6 · 2019: 1 · 2018: 5 · 2017: 5 · 2016: 2 · 2015: 12 · 2014: 9 · 2013: 7 · 2012: 7
FWCI
3.26
Type
journal article
Language
en
Open access
Locations
  • FEBS Journal (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • UWA Profiles and Research Repository (UWA) (submittedVersion)
Funders
  • National Institutes of Health
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR-052190, R01AR052190)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Vitamin D Research Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Steroid Chemistry and Biochemistry
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords
CYP11A1, cytochrome P450 side-chain cleavage, adrenal mitochondria, aminoglutethimide, keratinocytes, DNA synthesis inhibition
MeSH terms
Aminoglutethimide, Animals, Cattle, Cholesterol Side-Chain Cleavage Enzyme, Ergocalciferols, Humans, Hydroxycholecalciferols, Male, Magnetic Resonance Spectroscopy, Promoter Regions, Genetic, Protein Precursors, Keratinocytes, 25-Hydroxyvitamin D 2, Rats, Wistar, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review